Compare AstraZeneca plc (AZN) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Linde PLC — how do they compare? AstraZeneca plc trades at $168.02 (market cap $253.13B), while Linde PLC trades at $517.92 (market cap $241.59B). The key difference: AstraZeneca plc and Linde PLC are close in size by market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | LIN | |
|---|---|---|
Market Cap | $253.13B | $241.59B |
Sector | Health | Basic Materials |
52-Week High | $209.48 | $546.64 |
52-Week Low | $137.44 | $389.38 |
Enterprise Value | $279.37B | $263.95B |
Dividend Yield | 1.92% | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Linde (LIN) trades at $524.06, down 1.08% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.33 exceeding estimates, and robust profitability margins including a 20.44% net income margin. Analyst consensus is strongly bullish with a $560 price target, supported by positive cash flow trends and a recent dividend declaration.
Outlook remains positive due to steady revenue growth, high return on equity of 18.49%, and institutional confidence. Risks include elevated valuation multiples like a P/E of 34.65 and rising debt-to-asset ratio, which could pressure shares if earnings growth slows. The stock presents a quality holding for growth-oriented investors mindful of valuation constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
